EMPEROR-Reduced trial: larger benefit with empagliflozin vs. placebo for the composite of CV death or HFH in W (HR 0.59) than in M (HR 0.80)HF (5 RCTs; n = 21 948; 35.7% W): SGLT2 inhibitors reduced the composite of CV death and HFH, but the benefit was less pronounced in WT2D (3 CVOT; n = 34 322): SGLT2I reduced MACE in M, but not in WMeta-regression analysis (26 RCTs; n = 22 256; 58% W): significant reduction in all-cause mortality when the percentage of females was ≤50% but not when it was >50%. The gene discussed is SLC5A2; the disease is hydrops fetalis.